Premium Gefapixant API in Pakistan: Reliable Raw Material Supply for Pharmaceutical Formulators

Product Name: Gefapixant / Gefapixant Citrate (Active Pharmaceutical Ingredient)

Supplier / Distributor: Morgan

Therapeutic Category: P2X3 Receptor Antagonist

Indications: Refractory Chronic Cough (RCC), Unexplained Chronic Cough (UCC)

Compliance Notice: This technical data page is strictly for B2B pharmaceutical manufacturers, contract manufacturing organizations (CMOs), and analytical laboratories. The Gefapixant distributed by Morgan is a highly purified Active Pharmaceutical Ingredient (API) intended exclusively for commercial formulation and laboratory R&D. It is not a finished drug product.

About Morgan: Morgan Chemicals (Pvt.) Ltd. is a pharmaceutical raw material trading and distribution company. We source APIs from DRAP-registered and internationally certified manufacturers and supply exclusively to licensed pharmaceutical companies, CMOs, and research facilities. We do not manufacture APIs or sell finished medicines.

Product Overview and Mechanism of Action

Gefapixant is a first-in-class, non-narcotic, small-molecule Active Pharmaceutical Ingredient (API). In the field of respiratory pharmacology, it is classified as a highly selective purinergic P2X3 receptor antagonist, engineered specifically to address hyperactive cough disorders that do not respond to conventional treatments.

The mechanism of action for this API diverges completely from legacy centrally-acting antitussives (such as codeine or dextromethorphan). Under physiological stress, airway inflammation, or cellular injury, mucosal cells in the respiratory tract release high levels of extracellular adenosine triphosphate (ATP). This ATP acts as a damage-associated signaling molecule, binding directly to ATP-gated P2X3 ion channels located on the sensory C-fibers of the vagus nerve.

In patients with refractory chronic cough (RCC) or unexplained chronic cough (UCC), these sensory nerves are hypersensitized. By selectively binding to the P2X3 receptors, Gefapixant competitively blocks extracellular ATP from initiating the signal cascade. This targeted peripheral blockade drastically reduces the hyperactive cough reflex without crossing into the central nervous system, thereby avoiding the sedative and dependency risks associated with traditional cough suppressants.

For formulation scientists, integrating this API allows for the development of modern, targeted respiratory therapeutics. In commercial manufacturing, Gefapixant is predominantly formulated into 45 mg oral solid film-coated tablets.

Sourcing Gefapixant in Pakistan: Morgan’s Supply Network

Developing and commercializing novel respiratory formulations requires a highly resilient and fully traceable raw material pipeline. Procuring specialty APIs for local commercial manufacturing frequently involves navigating extended lead times, stringent customs bottlenecks, and complex regulatory compliance frameworks. Sourcing Gefapixant Pakistan through Morgan’s localized distribution network mitigates these supply chain risks.

Morgan sources commercial-scale and pilot-scale quantities from global manufacturing partners operating in strict adherence to ICH Q7 Good Manufacturing Practice (GMP) guidelines. Partnering with Morgan as your primary supply vendor secures several operational provisions for your manufacturing facility:

• DRAP Submission Assistance: Morgan coordinates with DRAP-registered API manufacturers to obtain and forward the necessary compliance documentation on your behalf. This includes the open part of the Drug Master File (DMF), comprehensive impurity profiles, and accelerated stability data to strictly support your Drug Regulatory Authority of Pakistan (DRAP) dossier submissions.
• Supply Chain Stability: Our localized API inventory management eliminates international transit variables. Whether your facility requires a small R&D batch or a high-volume Gefapixant api Pakistan procurement order, we help ensure that your commercial batch schedules and production timelines are met without costly line stoppages.
• Batch-to-Batch Uniformity: Every shipment coordinated by Morgan includes a detailed Certificate of Analysis (CoA) issued by the original manufacturer. We ensure our supplied batches maintain consistent chemical purity, controlled moisture limits, and a precise particle size distribution (PSD) for predictable behavior during blending, granulation, and compression processes.

Technical Specifications for QA & R&D

The Gefapixant API supplied by Morgan undergoes exacting analytical testing at the source to meet current international pharmacopeial standards.

• Chemical Name: 5-(2,4-diaminopyrimidin-5-yl)oxy-2-methoxy-4-propan-2-ylbenzenesulfonamide
• CAS Number: 1015787-98-0 (Free Base) / 2310299-91-1 (Citrate Salt)
• Appearance: White to off-white crystalline solid powder
• Molecular Formula: C14H19N5O4S
• Molecular Weight: 353.40 g/mol (Free Base)
• Assay / Purity (HPLC): ≥ 99.0%
• Solubility Profile: Detailed solubility parameters across standard organic solvents and aqueous buffers are documented in the technical data sheet to assist your analytical R&D teams with dissolution profiling and pre-formulation stability studies.

Manufacturing and Handling Guidelines for Formulators

Gefapixant is a pharmacologically active compound. Facilities processing this API must enforce strict occupational exposure limits (OEL) to protect personnel on the manufacturing floor and prevent cross-contamination.

• Storage Conditions: Store the raw API powder in securely closed, light-resistant containers. Maintain climate-controlled conditions as specified by the batch protocol (typically controlled room temperature, strictly protected from excessive heat and ambient humidity) to prevent chemical degradation.
• Occupational Safety: Personnel handling the pure API powder must follow advanced industrial containment protocols. Processing requires appropriate Personal Protective Equipment (PPE), including P3/N95 industrial dust masks or respirators, chemical-resistant nitrile gloves, and full protective facility garments. Dispensing, micronization, milling, and blending stages must be executed within localized exhaust ventilation systems or dedicated negative-pressure weighing booths to prevent the inhalation of airborne particulates.

Distributor Disclaimer: Morgan Chemicals is a pharmaceutical raw material trading and distribution company. This API is sourced from DRAP-registered, GMP-certified manufacturing partners. Morgan Chemicals does not manufacture APIs, does not hold DRAP manufacturing registration, and does not sell finished medicines. This product is supplied exclusively to licensed pharmaceutical companies, CMOs, and research facilities in Pakistan — not for individual or consumer sale.